In an increasingly interconnected global marketplace, understanding and adapting to the nuances of different markets is crucial for Market Access success. Our company supports pharma, biotech and medtech clients with Global Market Access and country-specific solutions in major markets such as the United States, France, Germany, Italy, Spain, Switzerland and the United Kingdom. Our agency Justin Stindt Consultants consists of experts with both Global Market Access expertise and local experience in all major markets. Our consultancy also has a broad network of local experts and partners in all major international markets to provide global solutions to our clients.
In each of these markets, our consulting firm leverages our expertise to tailor market access strategies that address specific challenges in each market while guaranteeing consistency with global strategy.
For more information on market access in a specific market (EU or US), click the links below:
Justin Stindt Consultants is your agency to support you with global Market Access
Justin Stindt Consultants is your consulting firm with experts who have extensive experience in Market Access in international markets. Our skilled consultants can help you with market access activities such as pricing and reimbursement strategies, funding pathways, early advice meetings, pricing negotiations, ad boards, early access programme feasibility assessments and dossier submissions, pricing and reimbursement dossier preparations and submissions etc.
For more information about the services our agency provides, go to Pricing & Reimbursement Strategy, Pricing & Reimbursement Dossiers, Payer & HTA Engagement.
Industries
Pharma
The Pharma industry is characterized by long research & development cycles and complex Market Access, but once successful, medicines can achieve universal reimbursement.
Biotech
The biotech industry faces largely the same challenges & opportunities as the pharma industry but in addition to this financing rounds and Business Development & Licensing discussions play a pivotal role on the road towards successful Market Access.
Medical Devices
While regulatory approval is typically faster for Medical Devices compared to medicines, Pricing & Reimbursement is typically more complex and fragmented. Market Access for Medical Devices is a dynamic process which needs to be strategically managed throughout the product lifecycle.
e-Health / Digital Health
Market Access pathways for E-Health / Digital Health solutions are emerging and span from pilot projects to regular reimbursement pathways in key markets.
Our News
Introducing the Joint Clinical Assessment (JCA) in the EU: Aiming to Enhance Access to Innovative Therapies but Risking to Duplicate HTA for the Industry
The Joint Clinical Assessment (JCA) process in the European Union marks a significant advancement in the evaluation of innovative therapies across member states. The primary
Pricing and Reimbursement France – Securing Early Reimbursement Through the Early Access Programs
France’s Reimbursed Early Access Programs (EAPs) allow for reimbursement of new medicines before traditional reimbursement and even before Marketing Authorization. Given that it may take
HAS Early Access Program: Positive Trends After Two Years
The Haute Autorité de Santé (HAS) has recently shared a two-year summary of its Early Access program. The highlights include: Additionally, in a stride towards
Pricing and Reimbursement in Germany – Possibility of price increases for legacy products
In an effort to control rising cost Germany introduced both a price freeze preventing price increases on legacy products effective from 2009 onwards and a
